NASDAQ:MLND - Millendo Therapeutics Stock Price, Forecast & News

Millendo Therapeutics trades on the NASDAQ under the ticker symbol "MLND."

Millendo Therapeutics Inc (NASDAQ:MLND) released its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by $0.04. View Millendo Therapeutics' Earnings History.

Millendo Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Millendo Therapeutics.

6 Wall Street analysts have issued 1 year target prices for Millendo Therapeutics' shares. Their forecasts range from $22.00 to $35.00. On average, they expect Millendo Therapeutics' stock price to reach $26.33 in the next twelve months. This suggests a possible upside of 236.3% from the stock's current price. View Analyst Price Targets for Millendo Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Millendo Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Millendo Therapeutics.

Headlines about MLND stock have been trending neutral recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Millendo Therapeutics earned a media sentiment score of 0.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Millendo Therapeutics.

Millendo Therapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 125,600 shares, an increase of 20.0% from the December 15th total of 104,700 shares. Based on an average trading volume of 54,700 shares, the days-to-cover ratio is currently 2.3 days. Currently, 1.5% of the company's stock are sold short. View Millendo Therapeutics' Current Options Chain.

Some companies that are related to Millendo Therapeutics include BioSpecifics Technologies (BSTC), DURECT (DRRX), AnaptysBio (ANAB), Aptorum Group (APM), Atreca (BCEL), Urovant Sciences (UROV), Verrica Pharmaceuticals (VRCA), Avedro (AVDR), Progenics Pharmaceuticals (PGNX), Merus (MRUS), ProQR Therapeutics (PRQR), Calithera Biosciences (CALA), Mersana Therapeutics (MRSN), Kindred Biosciences (KIN) and Lannett (LCI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Millendo Therapeutics investors own include International Paper (IP), ADMA Biologics (ADMA), Crispr Therapeutics (CRSP), Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Stemline Therapeutics (STML), AbbVie (ABBV), Kadmon (KDMN), Adaptimmune Therapeutics (ADAP) and Aerie Pharmaceuticals (AERI).

Shares of MLND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MLND stock can currently be purchased for approximately $7.83.

Millendo Therapeutics has a market capitalization of $105.47 million and generates $290,000.00 in revenue each year. The company earns $-27,190,000.00 in net income (profit) each year or ($17.58) on an earnings per share basis. Millendo Therapeutics employs 32 workers across the globe.View Additional Information About Millendo Therapeutics.

The official website for Millendo Therapeutics is http://www.millendo.com/.

Millendo Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MA, 48104. The company can be reached via phone at 734-845-9000 or via email at [email protected]